Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Quantum Biopharma (QNTM) Income from Continuing Operations (2019 - 2025)

Quantum Biopharma's Income from Continuing Operations history spans 7 years, with the latest figure at 2300748.0 for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 9.91% to 2300748.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 15460437.0, a 28.63% decrease, with the full-year FY2025 number at 15460437.0, up 4.38% from a year prior.
  • Income from Continuing Operations hit 2300748.0 in Q4 2025 for Quantum Biopharma, up from 4769697.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for QNTM hit a ceiling of 25292797.0 in Q2 2023 and a floor of 12708326.0 in Q2 2021.
  • Historically, Income from Continuing Operations has averaged 1323312.2 across 5 years, with a median of 3419591.0 in 2025.
  • Biggest five-year swings in Income from Continuing Operations: soared 294.09% in 2021 and later crashed 274.88% in 2023.
  • Tracing QNTM's Income from Continuing Operations over 5 years: stood at 12708326.0 in 2021, then skyrocketed by 144.3% to 5630055.0 in 2022, then plummeted by 227.7% to 7189574.0 in 2023, then skyrocketed by 70.88% to 2093300.0 in 2024, then decreased by 9.91% to 2300748.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for QNTM at 2300748.0 in Q4 2025, 4769697.0 in Q3 2025, and 4970401.0 in Q2 2025.